Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains—Should Psychosocial Life Impairment Be Considered a Comorbidity?
Authors:
- Gaetano LicataGLGaetano Licata
- Eugenia Veronica Di BrizziEBEugenia Veronica Di Brizzi
- Franco CastelliFCFranco Castelli
- Giorgia GiuffridaGGGiorgia Giuffrida
- Elena StroppianaESElena Stroppiana
- Annunziata DattolaADAnnunziata Dattola
- Antonio Giovanni RichettaARAntonio Giovanni Richetta
- Elena De ColECElena De Col
- Rossana PeilaRPRossana Peila
- Niccolò SiliquiniNSNiccolò Siliquini
- Carmen SolaroliCSCarmen Solaroli
- Roberta ZanettaRZRoberta Zanetta
Open Access
- 2 January 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (1) , 223
Abstract
Background/Objectives: Psoriasis is a chronic inflammatory skin disease that may have a significant impact on patients’ quality of life. Alongside clinical scores, treatment goals include improvements in patients’ quality of life, divided into its social, working and psychosocial life aspects. Indeed, psychological impairment should always be considered in the management of moderate-to-severe psoriasis. Tildrakizumab, an anti-IL-23, is approved for the management of moderate-to-severe psoriasis. Both clinical trials and real-life studies show its efficacy and safety; however, no studies have evaluated how tildrakizumab may improve different domains of quality of life, including physical, psychological, and social aspects of patients’ quality of life. The objective was to evaluate the effectiveness of tildrakizumab in the management of moderate-to-severe psoriasis, focusing on the impact on all domains of patients’ quality of life. Methods: A 28-week multicenter, real-life, retrospective study was performed enrolling patients affected by moderate-to-severe psoriasis undergoing treatment with tildrakizumab. PASI and DLQI were evaluated at each follow-up (W16, W28). A sub-analysis of each DLQI question evaluated different domains of quality of life, including physical, psychological, and social aspects of patients’ quality-of-life. Results: A total of 62 patients were enrolled. At week 28, 97.1%, 85.7%, and 54.3% of patients achieved PASI75, PASI90, and PASI100, respectively. DLQI showed a significant reduction from baseline (20.3 ± 5.5) to week 28 (0.9 ± 2.2, p < 0.0001), with up to 82.9% achieving DLQI < 1. Sub-analysis of each question (Q1–Q10) showed a reduction in the value of each answer from baseline to week 28. Conclusions: The results confirm tildrakizumab as an effective and safe treatment in real life, positively affecting all domains of quality of life, with significant impact already appreciable at week 16 of follow-up.Keywords
This publication has 31 references indexed in Scilit:
- Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28Journal of the European Academy of Dermatology and Venereology, 2019
- Psychological Profile of Patients with PsoriasisAnnals of the Academy of Medicine, Singapore, 2018
- Psychological Distress, Alexithymia and Alcohol Misuse in Patients with Psoriasis: A Cross-Sectional StudyJournal of Clinical Psychology in Medical Settings, 2018
- The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessmentAdvances in Clinical and Experimental Medicine, 2017
- Review of phase III trial data on IL‐23 inhibitors tildrakizumab and guselkumab for psoriasisJournal of the European Academy of Dermatology and Venereology, 2017
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsThe Lancet, 2017
- Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab TherapyDermatology and Therapy, 2014
- Patients’ Visual Analogue Scale: A Useful Method for Assessing Psoriasis SeverityActa Dermato-Venereologica, 2012
- Stress and quality of life in psoriasis: an updateInternational Journal of Dermatology, 2011
- Psychological influences in psoriasisClinical and Experimental Dermatology, 2001